TY - JOUR
T1 - Challenges in IBD Research
T2 - Precision Medicine
AU - Denson, Lee A.
AU - Curran, Mark
AU - McGovern, Dermot P.B.
AU - Koltun, Walter A.
AU - Duerr, Richard H.
AU - Kim, Sandra C.
AU - Sartor, R. Balfour
AU - Sylvester, Francisco A.
AU - Abraham, Clara
AU - de Zoeten, Edwin F.
AU - Siegel, Corey A.
AU - Burns, Richéal M.
AU - Dobes, Angela M.
AU - Shtraizent, Nataly
AU - Honig, Gerard
AU - Heller, Caren A.
AU - Hurtado-Lorenzo, Andrés
AU - Cho, Judy H.
N1 - Publisher Copyright:
© 2019 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2019/5/16
Y1 - 2019/5/16
N2 - Precision medicine is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, environmental triggers, novel technologies, and pragmatic clinical research. The Challenges in IBD Research document provides a comprehensive overview of current gaps in inflammatory bowel diseases (IBD) research and delivers actionable approaches to address them. It is the result of a multidisciplinary input from scientists, clinicians, patients, and funders, and represents a valuable resource for patient centric research prioritization. In particular, the precision medicine section is focused on highlighting the main gap areas that must be addressed to get closer to treatments tailored to the biological and clinical characteristics of each patient, which is the aim of precision medicine. The main gaps were identified in: 1) understanding and predicting the natural history of IBD: disease susceptibility, activity, and behavior; 2) predicting disease course and treatment response; and 3) optimizing current and developing new molecular technologies. Suggested approaches to bridge these gaps include prospective longitudinal cohort studies to identify and validate precision biomarkers for prognostication of disease course, and prediction and monitoring of treatment response. To achieve this, harmonization across studies is key as well as development of standardized methods and infrastructure. The implementation of state-of-the-art molecular technologies, systems biology and machine learning approaches for multi-omics and clinical data integration and analysis will be also fundamental. Finally, randomized biomarker-stratified trials will be critical to evaluate the clinical utility of validated signatures and biomarkers in improving patient outcomes and cost-effective care.
AB - Precision medicine is part of five focus areas of the Challenges in IBD research document, which also includes preclinical human IBD mechanisms, environmental triggers, novel technologies, and pragmatic clinical research. The Challenges in IBD Research document provides a comprehensive overview of current gaps in inflammatory bowel diseases (IBD) research and delivers actionable approaches to address them. It is the result of a multidisciplinary input from scientists, clinicians, patients, and funders, and represents a valuable resource for patient centric research prioritization. In particular, the precision medicine section is focused on highlighting the main gap areas that must be addressed to get closer to treatments tailored to the biological and clinical characteristics of each patient, which is the aim of precision medicine. The main gaps were identified in: 1) understanding and predicting the natural history of IBD: disease susceptibility, activity, and behavior; 2) predicting disease course and treatment response; and 3) optimizing current and developing new molecular technologies. Suggested approaches to bridge these gaps include prospective longitudinal cohort studies to identify and validate precision biomarkers for prognostication of disease course, and prediction and monitoring of treatment response. To achieve this, harmonization across studies is key as well as development of standardized methods and infrastructure. The implementation of state-of-the-art molecular technologies, systems biology and machine learning approaches for multi-omics and clinical data integration and analysis will be also fundamental. Finally, randomized biomarker-stratified trials will be critical to evaluate the clinical utility of validated signatures and biomarkers in improving patient outcomes and cost-effective care.
KW - Crohn’s disease
KW - biological signature
KW - biomarker
KW - deep phenotyping
KW - patient stratification
KW - precision medicine
KW - ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85066833217&partnerID=8YFLogxK
U2 - 10.1093/ibd/izz078
DO - 10.1093/ibd/izz078
M3 - Review article
C2 - 31095701
AN - SCOPUS:85066833217
SN - 1536-4844
VL - 25
SP - S31-S39
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
ER -